Home › Compare › VBIO vs MAIN

VBIO vs MAIN: Dividend Comparison 2026

VBIO yields 512.82% · MAIN yields 8.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VBIO wins by $74719.31M in total portfolio value
10 years
VBIO
VBIO
● Live price
512.82%
Share price
$0.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$74719.37M
Annual income
$54,003,807,702.14
Full VBIO calculator →
MAIN
Main Street Capital Corporation
● Live price
8.41%
Share price
$52.80
Annual div
$4.44
5Y div CAGR
5.1%
Payout ratio
82%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.2K
Annual income
$2,355.47
Full MAIN calculator →

Portfolio growth — VBIO vs MAIN

📍 VBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVBIOMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VBIO + MAIN cover 8 of 12 months — good coverage

Jan
MAIN
Feb
MAIN
Mar
—
Apr
—
May
—
Jun
—
Jul
MAIN
Aug
MAIN
Sep
MAIN
Oct
MAIN
Nov
MAIN
Dec
MAIN
VBIO pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VBIO
Annual income on $10K today (after 15% tax)
$43,589.74/yr
After 10yr DRIP, annual income (after tax)
$45,903,236,546.82/yr
MAIN
Annual income on $10K today (after 15% tax)
$714.77/yr
After 10yr DRIP, annual income (after tax)
$2,002.15/yr
At 15% tax rate, VBIO beats the other by $45,903,234,544.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VBIO + MAIN for your $10,000?

VBIO: 50%MAIN: 50%
100% MAIN50/50100% VBIO
Portfolio after 10yr
$37359.71M
Annual income
$27,001,905,028.81/yr
Blended yield
72.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

VBIO
No analyst data
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+23.6% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VBIO buys
0
MAIN buys
0
No recent congressional trades found for VBIO or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVBIOMAIN
Forward yield512.82% ✓8.41%
Annual dividend / share$2.00$4.44 ✓
Payout ratio50% ✓82%
1-year div growth0%3.7% ✓
5-year div CAGR0%5.1% ✓
Portfolio after 10y$74719.37M ✓$57.2K
Annual income after 10y$54,003,807,702.14 ✓$2,355.47
Total dividends collected$72929.43M ✓$15.5K
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: VBIO vs MAIN ($10,000, DRIP)

YearVBIO PortfolioVBIO Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$61,982$51,282.05$12,124$883.80+$49.9K → VBIO
2$363,383$297,062.31$14,629$1,001.91+$348.8K → VBIO
3$2,016,476$1,627,655.79$17,573$1,130.42+$2.00M → VBIO
4$10,598,885$8,441,255.59$21,022$1,269.75+$10.58M → VBIO
5$52,806,644$41,465,837.52$25,049$1,420.29+$52.78M → VBIO
6$249,582,121$193,079,012.24$29,738$1,582.45+$249.55M → VBIO
7$1,119,909,823$852,856,952.70$35,182$1,756.64+$1119.87M → VBIO
8$4,774,834,551$3,576,531,040.71$41,488$1,943.25+$4774.79M → VBIO
9$19,360,340,566$14,251,267,596.86$48,775$2,142.72+$19360.29M → VBIO
10$74,719,372,108$54,003,807,702.14$57,179$2,355.47+$74719.31M → VBIO

VBIO vs MAIN: Complete Analysis 2026

VBIO — Stock

Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug for inflammatory bowel disease and irritable bowel syndromes. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is headquartered in Los Angeles, California.

Full VBIO Calculator →

MAIN — BDC

Main Street Capital is a Business Development Company providing debt and equity capital to lower middle market companies. It pays regular monthly dividends plus semi-annual special dividends. One of the few BDCs consistently trading at a premium to NAV, with an exceptional track record since its 2007 IPO. Often called the gold standard of BDCs.

Full MAIN Calculator →
📬

Get this VBIO vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VBIO vs SCHDVBIO vs JEPIVBIO vs OVBIO vs KOVBIO vs ARCCVBIO vs HTGCVBIO vs GBDCVBIO vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.